Analyst consensus rating
Anika Therapeutics Analyst Rating: Strong Buy
Direct answer
Anika Therapeutics's consensus rating is Strong Buy.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $20.00.
Forecast evidence checked November 22, 2026.
Get free Anika Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.23
- Average price target
- $20.00
- High price target
- $23.00
- Low price target
- $17.00
- Low target gap
- +28.5%
- Target upside
- +51.2%
- High target gap
- +73.8%
- Target range width
- 45.4%
- Consensus rating
- Strong Buy
- Analysts
- 2
- Evidence date
- November 22, 2026
- Valid through
- November 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Anika Therapeutics?
Anika Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $20.00.
How far are Anika Therapeutics's low and high targets from the recorded price?
The low target implies +28.5%, while the high target implies +73.8%.
How many analysts are included in Anika Therapeutics's consensus?
The verified consensus includes 2 analysts.
How is Anika Therapeutics's target upside or downside calculated?
The average target of $20.00 is divided by the recorded price of $13.23, then one is subtracted to produce +51.2%. This does not guarantee a future return.
When was Anika Therapeutics's analyst forecast verified?
The data was verified on 2026-11-22. The dataset is valid through 2026-11-29.